组内相关
医学
可视模拟标度
结肠镜检查
食品药品监督管理局
比例(比率)
可靠性(半导体)
克罗恩病
生活质量(医疗保健)
相关性
内科学
疾病
胃肠病学
外科
心理测量学
药理学
结直肠癌
护理部
几何学
数学
功率(物理)
临床心理学
癌症
物理
量子力学
作者
Virginia Solitano,Corey A. Siegel,Joshua R. Korzenik,Jennifer K. Maratt,Douglas K. Rex,Bryan Maguire,Brian Bressler,J. Großmann,Rocío Sedaño,John WD McDonald,Julie Rémillard,Lisa M. Shackelton,Guangyong Zou,Brian G. Feagan,Christopher Ma,Vipul Jairath
摘要
Summary Background The performance of bowel preparation (BP) in patients with Crohn's disease (CD) is unknown. Aims To evaluate the operating properties of instruments used to assess BP quality in patients with CD. Methods We used the Boston Bowel Preparation Scale, modified Boston Bowel Preparation Scale, Harefield Cleansing Scale, Food and Drug Administration Bowel Cleansing Assessment Scale (BCAS), and a 100‐mm visual analogue scale of bowel cleanliness to assess BP quality in 50 videos from 40 patients with CD. We assessed endoscopic activity with the Simple Endoscopic Score for CD (SES‐CD). Assessments were on endoscope insertion and withdrawal. Reliability was quantified using the intraclass correlation coefficient (ICC). We assessed validity by within‐patient correlation between instruments and the visual analogue scale using mixed‐effect models. The correlation between BP quality and SES‐SD scores was assessed using Spearman's rho. Results Inter‐ and intra‐rater reliability for all BP quality instruments was substantial (ICC ≥0.61) except for the Food and Drug Administration BCAS on insertion (inter‐rater reliability ICC ≥0.41). The visual analogue scale had substantial inter‐ and almost perfect (ICC ≥0.81) intra‐rater reliability. Correlation coefficients for the validity of the instruments exceeded 0.58. BP quality and endoscopic disease activity scores in the colon were negatively correlated. Conclusion Most existing instruments reliably assess BP quality in patients with CD. These results support the use of these instruments in clinical practice, provide a framework for scoring BP quality in CD clinical trials, and support evaluation of novel BP agents in patients with CD.
科研通智能强力驱动
Strongly Powered by AbleSci AI